Targeted inhibition of coagulation: oral agents show promise in phase III trials

K A Bauer¹

Affiliations

Free article

Review

K A Bauer. J Thromb Haemost. 2007 Nov.

Free article

. 2007 Nov;5(11):2175-7.

doi: 10.1111/j.1538-7836.2007.02742.x. Epub 2007 Aug 22.

K A Bauer¹

¹ VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02130, USA. kbauer@bidmc.harvard.edu

No abstract available

Comment on

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR; RE-MODEL Study Group. Eriksson BI, et al. J Thromb Haemost. 2007 Nov;5(11):2178-85. doi: 10.1111/j.1538-7836.2007.02748.x. J Thromb Haemost. 2007. PMID: 17764540 Clinical Trial.